TNFSF10 and non-small cell lung carcinoma: This study has demonstrated that the sensitizing of NSCLC cell lines and their CSCs, specifically the TRAIL-resistant A549 cell line, using first-line chemotherapies could enhance the effect of MSC-TRAIL against NSCLC.